^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    viagenpumatucel-L (HS-110)

    i
    Other names: HS-110, HS110 vaccine, HS-L1 therapeutic vaccine
    Company:
    Scorpius Holdings
    Drug class:
    Endoplasmin modulator, Endoplasmin stimulant
    over3years
    [VIRTUAL] TetTCRII-SeqHD: High-dimensional analysis of antigen-specific ex vivo CD4+ T cells (IMMUNOLOGY 2021)
    We also found explicit differences in the phenotypes of antigen specific cells within the tumor and a paired healthy tissue sample. Conclusions In conclusion, we validate the use of a high-throughput technology for assessing the specificity, phenotype, TCR, and gene expression patterns in antigen-specific CD4+ T cells in peripheral blood and tumor infiltrating lymphocytes.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    viagenpumatucel-L (HS-110) • gp96-Ig vaccine
    over4years
    [VIRTUAL] Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes (ESMO 2020)
    Legal entity responsible for the study: Heat Biologics, Inc. Funding: Heat Biologics, Inc.
    Clinical • Tumor-Infiltrating Lymphocyte
    |
    CD8 (cluster of differentiation 8)
    |
    TILs
    |
    Opdivo (nivolumab) • viagenpumatucel-L (HS-110)
    over4years
    [VIRTUAL] Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. (ASCO 2020)
    The combination of HS-110 and nivolumab appears safe and well tolerated. OS was improved in pts whose tumors express ≥ 8 shared antigens with HS110, as well as in those who specifically expressed ZNF492. Further exploration of antigen expression as a predictor for treatment outcome with HS110 plus nivolumab is ongoing.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • viagenpumatucel-L (HS-110)